CNTB — Connect Biopharma Holdings Cashflow Statement
0.000.00%
- $45.67m
- -$48.04m
- $26.03m
- 34
- 53
- 30
- 33
Annual cashflow statement for Connect Biopharma Holdings, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | R2021 December 31st | R2022 December 31st | R2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 20-F | 20-F | 10-K | 10-K |
Standards: | IFRS | IFRS | IFRS | USG | USG |
Status: | fx Final | Final | Final | Final | Final |
Net Income/Starting Line | -113 | -202 | -118 | -62.1 | -15.6 |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | 88.9 | 113 | 8.78 | 3.79 | 6.85 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -0.413 | 3.58 | 6.46 | 9.85 | -15.5 |
Change in Accounts Receivable | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Payable / Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -24.2 | -84.3 | -102 | -47.7 | -23.6 |
Capital Expenditures | -2.22 | -3.88 | -4.41 | -0.081 | -0.75 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | 2.64 | -1.32 | -81.8 | 75.1 | -2.7 |
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | 0.425 | -5.21 | -86.2 | 75 | -3.45 |
Financing Cash Flow Items | -0.572 | -17.1 | 0 | 0.044 | 0.033 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 133 | 202 | -0.085 | 0.045 | 0.227 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 102 | 113 | -189 | 26.7 | -27.4 |